Application of Prkar1a as target for treating obesity and complications thereof

By specifically knocking out the Prkar1a gene in liver, the PKA signaling pathway is activated, and individual differences and side effects in existing obesity treatment methods are solved, effective treatment of obesity and its complications is achieved, and the weight and blood lipid levels in mice are significantly reduced. Improve insulin sensitivity.

CN118995760APending Publication Date: 2024-11-22ANHUI MEDICAL UNIV
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410714749.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-04
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing treatment methods for obesity and its complications have problems such as large individual differences, serious side effects, unclear mechanism of action and low drug clearance, making it difficult to achieve effective and safe long-term treatment effects.

Method used

The specific knockdown of the Prkar1a gene mediated by AAV8 adeno-associated viral vectors activates the PKA signaling pathway, reduces mouse weight, blood lipids and hepatic lipid levels, and improves insulin sensitivity, as a therapeutic target for obesity and its complications.

Benefits of technology

Significantly reduces the weight and fat tissue weight of mice induced by a high-fat diet, reduces blood lipid levels, and improves insulin resistance symptoms, providing new potential targets and methods for treating obesity and its complications without obvious side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995760A_ABST
    Figure CN118995760A_ABST
Patent Text Reader

Abstract

The invention discloses application of Prkar1a as a target for treating obesity and complications thereof, and belongs to the technical field of gene functions and application. A mouse with Prkar1a specifically knocked out of the liver is used as an experimental subject, a mouse model with obesity and complications thereof is induced through high fat diet, and the result shows that specific knockout of the mouse liver Prkar1a gene to activate a PKA signal can be used as a means for clinical treatment of obesity and complications thereof, and no obvious toxic or side effect exists; the composition is expected to be applied to people with body weight control and body nutrition energy metabolism improvement requirements clinically, and the purpose of improving the human health level is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of gene function and application, and in particular to an application of Prkar1a as a target for the treatment of obesity and its complications. Background Art

[0002] Obesity and its complications are major challenges facing global public health. It is estimated that by 2030, the number of obese people in the world will exceed 1 billion, and has been growing rapidly for many years. Obesity often causes a series of complications, including type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, hyperlipidemia, hypertension, metabolic syndrome and certain types of cancer, which seriously affect human health.

[0003] Obesity is caused by excessive accumulation of body fat due to an imbalance between energy intake and expenditure, and its pathogenic factors include both genetics and the environment. The treatment methods and strategies for obesity are also diverse. However, current treatment measures have their own limitations and shortcomings, which limit their clinical effects to a certain extent. For example, eating habits are often affected by social factors such as culture and lifestyle and are difficult to change effectively; increasing exercise is difficult to achieve lasting weight loss effects; liposuction surgery has high risks, and the individual differences in surgical effects are large and uncontrollable. Among them, drug therapy is still an important way to treat obesity and its complications, and has achieved relatively significant clinical effects in the long-term treatment of obesity. Currently, the drugs approved for marketing include orlistat, phentermine, topiramate, and artesunate. However, current drug treatments still face many challenges: (1) The treatment effects vary greatly among different individuals, making it difficult to achieve personalization and universal high efficiency; (2) Many drugs produce serious side effects and damage to the nervous system and cardiovascular system, and their safety is not high enough; (3) The mechanism of action of some drugs is not yet clear, resulting in potential off-target toxicity; (4) Some drugs have low clearance rates, which can easily cause long-term drug accumulation in tissues and organs and damage health. Therefore, it is urgent to develop new drugs for the treatment of obesity to improve the effectiveness and safety of current treatments.

[0004] Generally speaking, in addition to abnormally high body weight, obese patients are often accompanied by hyperglycemia, hyperlipidemia, and abnormal accumulation of lipids in organ tissues caused by disorders in the body's nutritional energy metabolism. Current obesity treatment urgently needs to comprehensively combat obesity and its series of complications, so as to achieve good long-term treatment effects and reduce recurrence. Since the body's nutritional and energy metabolism regulatory signals present complex network regulatory characteristics, and various metabolic pathways and pathways are highly cross-interactive, clinical measures for the treatment of obesity must minimize side effects on other metabolic aspects of the body and improve the overall safety of treatment. Systemic intervention in metabolic regulatory factors often leads to serious side effects, and the inability to effectively guarantee safety has greatly limited its clinical application.

[0005] The cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) signaling pathway is one of the intracellular signal transduction pathways mediated by G protein-coupled receptors (GPCRs), which is involved in the regulation of various physiological processes in cells. The PKA holoenzyme protein consists of two regulatory subunits (PRKAR1A and PRKAR1B) and two catalytic subunits (PRKACA and PRKACB), and each subunit has different subtypes. We found that specific knockout of the gene encoding liver PRKAR1A, Prkar1a, to activate PKA signaling can effectively reduce the body weight of mice, while there are no other obvious side effects, suggesting that specific interference with liver PRKAR1A and activation of PKA signaling can effectively treat obesity. Summary of the invention

[0006] In order to solve the above-mentioned defects and shortcomings of the prior art, the primary purpose of the present invention is to provide an application of Prkar1a as a target for the treatment of obesity and its complications.

[0007] Another object of the present invention is to provide a method for constructing a liver-specific Prkar1a knockout mouse and detecting related indicators. To achieve the above object, the technical solution provided by the present invention is as follows:

[0008] The present invention uses AAV8 adeno-associated virus vector-mediated liver-specific knockout Prkar1a mice as experimental subjects, and induces obesity and its complications mouse model through a high-fat diet. The results show that: compared with control mice, specific knockout of the Prkar1a gene in the liver of mice significantly reduces the body weight, liver weight and adipose tissue weight of mice fed with a high-fat diet; specific knockout of Prkar1a in the liver of mice significantly reduces blood lipid and liver fat levels, and reduces liver lipid accumulation; in addition, the insulin sensitivity of mice with specific knockout of Prkar1a in the liver is significantly improved, effectively improving the symptoms of insulin resistance. This suggests that Prkar1a can be used as a target for the clinical treatment of obesity and its complications, and provides new ideas and application prospects for the development of new weight-loss drugs and clinical treatment methods.

[0009] In view of the above-mentioned functions of Prkar1a, the present invention provides an application of Prkar1a as a target for the treatment of obesity and its complications, and the application includes but is not limited to: the application of Prkar1a as a target for the treatment of obesity, the application of Prkar1a as a target for the treatment of diabetes, the application of Prkar1a as a target for the treatment of hyperlipidemia, the application of Prkar1a as a target for the treatment of hypertension, the application of Prkar1a as a target for the treatment of atherosclerosis, the application of Prkar1a as a target for the treatment of cardiovascular diseases, the application of Prkar1a as a target for the treatment of fatty liver-related diseases, and the application of Prkar1a as a target for the treatment of diseases related to enhanced insulin sensitivity.

[0010] The use is for non-diagnostic and non-therapeutic purposes.

[0011] The present invention provides a therapeutic target for obesity and its complications, wherein the therapeutic target for obesity and its complications is Prkar1a.

[0012] The present invention provides a detection method using Prkar1a as a therapeutic target for obesity and its complications. The detection method comprises: using AAV8 adeno-associated virus vector-mediated liver-specific Prkar1a knockout mice as experimental subjects, inducing obesity and its complications mouse models through a high-fat diet, and measuring indicators compared with control mice to obtain detection results.

[0013] The index determination includes at least one of body weight measurement, insulin tolerance test, determination of triglyceride (TG) and total cholesterol (TC) content in serum and liver samples, and determination of liver lipid accumulation.

[0014] The application includes the application after the deletion, expression inhibition or inactivation of the Prkar1a gene or its encoding protein and the application of the Prkar1a gene or its encoding protein as a target.

[0015] For details of the Prkar1a gene in the present invention, see the National Center for Biotechnology Information database (NCBI Genbank, https: / / www.ncbi.nlm.nih.gov) (human gene ID: 5573; mouse gene ID: 19084). The deletion, expression inhibition or inactivation of the Prkar1a gene or its encoded protein can be achieved by conventional molecular cell biology methods, such as viral vector-mediated gene editing, gene silencing, expression of dominant negative mutants, PKA activity agonists, etc.

[0016] The aforementioned applications of the present invention are for non-diagnostic and non-therapeutic purposes.

[0017] On the other hand, the present invention provides a method for constructing a liver-specific Prkar1a knockout mouse and detecting related indicators, which specifically includes:

[0018] (1) Designing a specific sgRNA for the Prkar1a sequence and cloning it into an AAV8 viral vector plasmid containing the liver-specific promoter TBG to initiate the recombinase Cre expression sequence to obtain the AAV8-TBG.Cre.U6.sgPrkar1a plasmid;

[0019] (2) transfecting the above plasmid into HEK293t cells cultured in vitro to express and self-assemble to produce AAV8-TBG.Cre.U6.sgPrkar1a virus particles, collecting the virus fluid and purifying it;

[0020] (3) The virus solution was injected into the tail vein to infect conditional Cas9 knock-in mice (Rosa26-CAG-LSL-Cas9), causing them to express Cre specifically in the liver, thereby initiating the specific expression of Cas9 in hepatocytes. At the same time, Prkar1asgRNA was expressed, thereby achieving hepatocyte-specific silencing of Prkar1a (Prkar1a LKO mice);

[0021] (4) More than one week after virus injection, serum and other tissue samples were collected for testing and analysis.

[0022] Furthermore, the nucleotide sequence of the sgRNA is shown in SEQ ID NO: 1 and SEQ ID NO: 2.

[0023] SEQ ID NO: 1 and SEQ ID NO: 2 are 5'-TGC TGC CTC CTA CGT TAG AA-3' and 5'-ACC TTG ATG ATA ACG AGA GA-3', respectively.

[0024] Furthermore, the nucleotide sequence of the AAV8-TBG.Cre.U6.sgPrkar1a plasmid is shown in SEQ ID NO: 3.

[0025] Further, the AAV8-TBG.Cre.U6.sgPrkar1a plasmid map is as follows Fig.10 shown.

[0026] Furthermore, the full name of the LSL Cas9 is Rosa26-CAG-LSL-Cas9, which was purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.

[0027] Furthermore, the Prkar1a LKO: AAV8-TBG.Cre.U6.sgPrkar1a plasmid was packaged into AAV8 virus and injected into Rosa26-CAG-LSL-Cas9 mice through the tail vein to obtain Prkar1a LKO mice.

[0028] The present invention provides a new application for treating obesity and its complications by regulating the body's energy metabolism through specific interference with liver Prkar1a, achieving a significant therapeutic effect without significant side effects.

[0029] The present invention verifies at the individual mouse level that liver-specific deletion of Prkar1a reduces body lipid accumulation, enhances insulin sensitivity and resists obesity induced by a high-fat diet. The present invention confirms that only liver-specific deletion of a regulatory subunit of a metabolic regulatory factor, PKA, PRKAR1A, can significantly resist the symptoms of weight gain, lipid accumulation and decreased insulin sensitivity induced by a high-fat diet, and no obvious toxic side effects are observed. It is expected to be applied to people who need to control their weight and improve their body's nutritional energy metabolism in the clinic, so as to achieve the purpose of improving human health.

[0030] Beneficial effects of the present invention:

[0031] (I) The present invention provides a potential new target for obesity drug treatment

[0032] Compared with control mice, specific knockout of the Prkar1a gene in the liver of mice significantly reduced the body weight of mice fed a high-fat diet ( Figure 3 A and B) and liver weight ( Figure 4 ); at the same time, the weight of inguinal white adipose tissue (iWAT) and brown adipose tissue (BAT) also decreased significantly, and the weight of epididymal white adipose tissue (eWAT) showed a decreasing trend ( Figure 5 ). This result shows that specific knockout of liver Prkar1a can effectively resist the occurrence of obesity induced by high-fat diet.

[0033] (II) It has a significant effect on alleviating the hyperlipidemia and fatty liver symptoms associated with obesity

[0034] Compared with control mice, specific knockout of Prkar1a in the liver of mice significantly reduced serum triglyceride (TG) and total cholesterol (TC) levels ( Figure 6 ), which has a significant effect on alleviating the hyperlipidemia symptoms associated with obesity. At the same time, the results of Oil Red O staining of liver sections showed that specific knockout of Prkar1a in the liver of mice significantly reduced the liver lipid accumulation caused by a high-fat diet ( Figure 7 ); accordingly, the level of triglycerides in the liver decreased significantly ( Figure 8) The results showed that specific knockout of hepatic Prkar1a could effectively resist fatty liver associated with obesity.

[0035] (III) Effectively improving insulin resistance and abnormal glucose metabolism symptoms associated with obesity

[0036] Under the condition of high-fat diet feeding, the insulin sensitivity of mice with specific knockout of hepatic Prkar1a was significantly improved compared with that of the control group mice ( Fig. 9 ), thus effectively improving insulin resistance and abnormal glucose metabolism symptoms associated with obesity. Description of the Drawings

[0037] Figure 1 It is a graph for detecting the knockout efficiency of Prkar1a in the liver of mice by qPCR; (wherein, Control represents the control group, Prkar1a LKO represents the group with specific knockout of Prkar1a in the liver; the ribosomal protein L32 mRNA level was used as the internal reference gene for calculation and analysis; the results were expressed as mean ± standard error (SEM); n≥6 independent samples).

[0038] Figure 2 It is a graph for detecting the knockout efficiency of Prkar1a in the liver of mice by western blotting; (wherein, Control represents the control group, Prkar1a LKO represents the group with specific knockout of Prkar1a in the liver; the tubulin level was used as the loading control; n = 3 independent samples).

[0039] Figure 3 It is a graph of the body weight change of mice under the condition of high-fat diet; (wherein, Control represents the control group, Prkar1a LKO represents the group with specific knockout of Prkar1a in the liver; Figure A is the actual body weight (g) of mice within 9 days after AAV8 virus injection; Figure B is the body weight change value (g) of mice within 12 days after AAV8 virus injection; the results were expressed as mean ± standard error (SEM); n≥7 independent samples; 0.01 < p < 0.05 is significant difference (*), 0.001 < p < 0.01 is extremely significant difference (**), 0.0001 < p < 0.001 is extremely extremely significant difference (***)).

[0040] Figure 4 It is the change of the liver weight / body weight percentage of mice under the condition of high-fat diet; (wherein, Control represents the control group, Prkar1a LKO represents the group with specific knockout of Prkar1a in the liver; the results were expressed as mean ± standard error (SEM); n≥8 independent samples; 0.01 < p < 0.05 is significant difference (*)).

[0041] Figure 5Changes in adipose tissue weight of mice under high-fat diet conditions; (where Control represents the control group, Prkar1a LKO represents the group with liver-specific knockout of Prkar1a; eWAT represents epididymal white fat, iWAT represents inguinal white fat, BAT represents brown fat; results are expressed as mean ± standard error (SEM); n ≥ 8 independent samples; p > 0.05 is non-significant difference (ns), 0.01 < p < 0.05 is significant difference (*), 0.001 < p < 0.01 is highly significant difference (**), 0.0001 < p < 0.001 is extremely highly significant difference (***), and so on).

[0042] Figure 6 Changes in serum lipid content of mice under high-fat diet conditions; (where Control represents the control group, Prkar1a LKO represents the group with liver-specific knockout of Prkar1a; A represents serum triglyceride content, B represents serum total cholesterol content; results are expressed as mean ± standard error (SEM); n ≥ 8 independent samples; p > 0.05 is non-significant difference (ns), 0.01 < p < 0.05 is significant difference (*), 0.001 < p < 0.01 is highly significant difference (**), 0.0001 < p < 0.001 is extremely highly significant difference (***), and so on).

[0043] Figure 7 Detection of lipid accumulation in the liver of mice under high-fat diet conditions by oil red O staining of frozen sections; (where Control represents the control group, Prkar1a LKO represents the group with liver-specific knockout of Prkar1a; red dots indicate lipid droplets; the shown are representative pictures; scale bar: 100 μm).

[0044] Figure 8 Changes in liver triglyceride content of mice under high-fat diet conditions; (where Control represents the control group, Prkar1a LKO represents the group with liver-specific knockout of Prkar1a; results are expressed as mean ± standard error (SEM); n ≥ 8 independent samples).

[0045] Fig. 9For mouse insulin sensitivity test; (where Control represents the control group and Prkar1a LKO represents the liver-specific Prkar1a knockout group; the figure shows the blood glucose levels (mmol / L) of mice within 120 minutes after acute insulin injection; the results are expressed as mean ± standard error of the mean (SEM); n ≥ 8 independent samples; p > 0.05 indicates no significant difference (ns), 0.01 < p < 0.05 indicates significant difference (*), 0.001 < p < 0.01 indicates extremely significant difference (**), 0.0001 < p < 0.001 indicates extremely extremely significant difference (***), and so on).

[0046] Fig.10 It is the plasmid map of AAV8-TBG.Cre.U6.sgPrkar1a. Detailed implementation manners

[0047] To enable those skilled in the art to better understand the technical solutions of the present invention, some non-limiting embodiments are further disclosed below to further elaborate on the present invention in detail.

[0048] The experimental methods of the present invention, unless otherwise specified, are all conventional technical methods in the art and are carried out according to the technical conditions described in professional literature or the relevant product specifications; the materials, reagents, etc. used, unless otherwise specified, can be obtained from commercial channels.

[0049] Statistical analysis was performed using GraphPad Prism 9 software. The results are expressed as mean ± standard error of the mean (SEM), and the differences between groups were analyzed by Student's t-test. p > 0.05 indicates no significant difference (ns), 0.01 < p < 0.05 indicates significant difference (*), 0.001 < p < 0.01 indicates extremely significant difference (**), 0.0001 < p < 0.001 indicates extremely extremely significant difference (***), and so on.

[0050] Example 1 Construction of mice with liver-specific knockout of Prkar1a mediated by AAV8-type adeno-associated virus vector

[0051] Experimental method:

[0052] (1) Design specific sgRNA against the Prkar1a sequence and clone it into the AAV8 virus vector plasmid to obtain the AAV8-TBG.Cre.U6.sgPrkar1a plasmid.

[0053] (2) Transfect the above plasmid into HEK293t cells cultured in vitro for expression and self-assembly to generate AAV8-sgPrkar1a virus particles, collect the virus solution and purify it.

[0054] (3) The virus solution was injected into the tail vein of conditional Cas9 knock-in mice (Rosa26-CAG-LSL-Cas9) to express Cre specifically in the liver, thereby initiating the specific expression of Cas9 in hepatocytes. At the same time, Prkar1a sgRNA was expressed, and Prkar1a was specifically silenced in hepatocytes (Prkar1a LKO mice). The control group mice (Control) were introduced with the control sgRNA in the same way.

[0055] (4) More than one week after virus injection, serum and other tissue samples were collected for testing and analysis.

[0056] Experimental results:

[0057] Figure 1 qPCR test results showed that the mRNA level of Prkar1a gene transcription in the liver of Prkar1a LKO mice was significantly lower than that in the control group, and the knockout efficiency exceeded 90%; Figure 2 Western blotting results showed that the protein level of Prkar1a gene translation in the liver of Prkar1a LKO mice was significantly lower than that in the control group. These results indicate that the method used in the present invention successfully obtained liver-specific Prkar1a knockout mice.

[0058] Example 2 Construction of a mouse model of high-fat diet-induced obesity and its complications and determination of indicators

[0059] Experimental methods:

[0060] (1) At 8 weeks of age, LSL Cas9 mice were fed the Research Diet high-fat formula (Research diet, No. D12492). The mice were allowed to eat and drink freely, and their body weight was measured and recorded every few days. After about 16 weeks, when the body weight was about 45 g and the body was significantly obese, the model was successfully established and then used for downstream experimental steps such as virus injection.

[0061] (2) After injection of the control and Prkar1a KO viruses, mice were continued to be fed a high-fat diet and their body weights were measured regularly. On the 10th day, an insulin tolerance test was performed.

[0062] (3) On the 14th day, the mice were killed and dissected to obtain the corresponding tissues, organs and serum samples, which were weighed and measured.

[0063] (4) The triglyceride (TG) and total cholesterol (TC) contents in serum and liver samples were determined according to the instructions of the kit (Nanjing Jiancheng).

[0064] (5) Prepare frozen sections of liver samples and use Oil Red O staining to show the lipid accumulation in the liver.

[0065] (6) The insulin tolerance test (ITT) was used to evaluate the insulin sensitivity of the model mice. The specific method was as follows: after the mice were starved for 4 hours, insulin (0.75 U / Kg body weight) was injected, and the serum glucose levels were measured at 0, 15, 30, 60 and 120 minutes.

[0066] Experimental results:

[0067] (1) Figure 3 A and B show that under high-fat diet feeding conditions, the body weight of control mice was always maintained at a high level, while the body weight of Prkar1a LKO mice began to gradually decrease about 1 week after virus injection, and was significantly lower than that of control mice after the 12th day.

[0068] (2) Figure 4 The results showed that under high-fat diet feeding conditions, the liver weight / body weight ratio of Prkar1a LKO mice was significantly lower than that of control mice; Figure 5 The results showed that the weight of inguinal white adipose tissue (iWAT) and brown adipose tissue (BAT) in Prkar1a LKO mice was also significantly reduced, and the weight of epididymal white adipose tissue (eWAT) tended to decrease.

[0069] (3) Figure 6 The results of serum sample lipid measurement showed that under high-fat diet feeding conditions, the serum triglyceride (TG) and total cholesterol (TC) levels of Prkar1a LKO mice were significantly lower than those of control mice.

[0070] (4) Figure 7 Oil red O staining of liver sections showed that under high-fat diet feeding conditions, a large number of lipid droplets were obviously accumulated in the livers of control mice, while the number and size of lipid droplets in the livers of Prkar1a LKO mice were significantly reduced; Figure 8 The results of liver triglyceride measurement showed that under high-fat diet feeding conditions, the liver triglyceride (TG) content of Prkar1a LKO mice was significantly lower than that of control mice. These results indicate that liver-specific deletion of Prkar1a significantly resists liver lipid accumulation caused by a high-fat diet.

[0071] (5) Fig. 9 The results of the insulin sensitivity test showed that under high-fat diet feeding conditions, the blood glucose levels of control mice decreased less and more slowly in response to exogenous insulin supplementation, while the blood glucose levels of Prkar1a LKO mice decreased more and more rapidly after exogenous insulin supplementation. This indicates that liver-specific deletion of Prkar1a significantly improves the body's insulin sensitivity.

[0072] The method of the present invention has been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein within the content, spirit and scope of the present invention to implement and apply the technology of the present invention. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention.

Claims

1. A therapeutic target for obesity and its complications, characterized in that: The therapeutic target for obesity and its complications is Prkar1a (human gene ID: 5573; mouse gene ID: 19084).

2. A detection method using Prkar1a as a therapeutic target for obesity and its complications, characterized in that: The detection method includes: using AAV8 adeno-associated virus vector-mediated liver-specific Prkar1a knockout mice as experimental subjects, inducing obesity and its complications mouse model through a high-fat diet, and measuring indicators compared with control mice to obtain detection results.

3. The detection method of using Prkar1a as a therapeutic target for obesity and its complications according to claim 2, characterized in that: Specifically include: (1) Designing a specific sgRNA for the Prkar1a sequence and cloning it into an AAV8 viral vector plasmid containing the liver-specific promoter TBG to initiate the recombinase Cre expression sequence to obtain the AAV8-TBG.Cre.U6.sgPrkar1a plasmid; (2) transfecting the above plasmid into HEK293t cells cultured in vitro to express and self-assemble to produce AAV8-TBG.Cre.U6.sgPrkar1a virus particles, collecting the virus fluid and purifying it; (3) Conditional Cas9 knock-in mice (Rosa26-CAG-LSL-Cas9) were injected with viral fluid through the tail vein to express Cre specifically in the liver, thereby initiating the specific expression of Cas9 in hepatocytes and at the same time expressing Prkar1a sgRNA, thereby achieving hepatocyte-specific silencing of Prkar1a (Prkar1a LKO mice); (4) More than one week after virus injection, serum and other tissue samples were collected for testing and analysis.

4. The detection method of using Prkar1a as a therapeutic target for obesity and its complications according to claim 3, characterized in that: In step (1), the nucleotide sequences of sgRNA are as follows: 5'-TGC TGC CTC CTA CGT TAG AA-3', and 5'-ACC TTG ATG ATA ACG AGA GA-3'.

5. The detection method of using Prkar1a as a therapeutic target for obesity and its complications according to claim 3, characterized in that: In the step (1), the nucleotide sequence of the AAV8-TBG.Cre.U6.sgPrkar1a plasmid is shown in SEQ ID NO:

3.

6. The detection method of using Prkar1a as a therapeutic target for obesity and its complications according to claim 2, characterized in that: The index determination includes at least one of body weight measurement, insulin tolerance test, determination of triglyceride (TG) and total cholesterol (TC) content in serum and liver samples, and determination of liver lipid accumulation.

7. The detection method of using Prkar1a as a therapeutic target for obesity and its complications according to claim 3, characterized in that: In the step (3), the full name of the LSL Cas9 is Rosa26-CAG-LSL-Cas9, which was purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.

8. The method for detecting Prkar1a as a therapeutic target for obesity and its complications according to claim 3, characterized in that: In the step (3), the Prkar1a LKO: AAV8-TBG.Cre.U6.sgPrkar1a plasmid is packaged into AAV8 virus and injected into Rosa26-CAG-LSL-Cas9 mice through the tail vein to obtain Prkar1a LKO mice.

9. An application of Prkar1a as a therapeutic target for obesity and its complications in the preparation of a drug for the treatment of obesity and its complications, wherein the application is for non-diagnostic and non-therapeutic purposes.

10. The use according to claim 5, characterized in that The obesity and its complications include at least one of the following: the use of Prkar1a as a target for the treatment of obesity, the use of Prkar1a as a target for the treatment of diabetes, the use of Prkar1a as a target for the treatment of hyperlipidemia, the use of Prkar1a as a target for the treatment of hypertension, the use of Prkar1a as a target for the treatment of atherosclerosis, the use of Prkar1a as a target for the treatment of cardiovascular diseases, the use of Prkar1a as a target for the treatment of fatty liver-related diseases, and the use of Prkar1a as a target for the treatment of diseases related to enhanced insulin sensitivity.

Citation Information

Cited By

  • Construction method and application of animal obesity model

    CN121444888A

  • A method for constructing and applying an animal obesity model

    CN121444888B